Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Almac Diagnostics Assay Identifies Link to Immune Response Mechanism | Contract Pharma

What are you searching for?

Sign in
Breaking News

Almac Diagnostics Assay Identifies Link to Immune Response Mechanism

Study provides observed link between DNA repair deficiency and activation of the immune checkpoint PD-L1

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac Group’s Diagnostics business has identified a novel immune response mechanism in breast tumors deficient in DNA repair. The current study explains the molecular basis of this 44-gene immune based assay and demonstrates that the genes in the assay reflect activation of the innate immune response cGAS/STING/TBK1/IRF3 pathway in response to DNA damage.
 
The study provides rationale for the observed link between DNA repair deficiency and activation of the immune checkpoint PD-L1. Almac will now pursue their 44-gene assay as a means of prospectively identifying breast cancer patients likely to respond to PD-L1 targeted therapies.
 
Professor Richard Kennedy, MD, Ph.D., McClay Professor in Medical Oncology, Queens University Belfast and vice president and medical director, Almac Diagnostics said “The study provides strong justification for the underlying biology that causes enhanced PD-L1 expression. Almac will now engage with pharma and academia to investigate the potential clinical benefit for predicting response to immune checkpoint inhibitors, such as PD-L1 and IDO1 and their use in combination with DNA damaging agents.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters